Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 817427, 4 pages
http://dx.doi.org/10.1155/2015/817427
Research Article

Anti-CCP Antibody Levels Are Not Associated with MS: Results from a Case-Control Study

1Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Yuzuncu Yil University, 65100 Van, Turkey
2Department of Neurology, Faculty of Medicine, Yuzuncu Yil University, 65100 Van, Turkey
3Department of Medical Microbiology, Faculty of Medicine, Yuzuncu Yil University, 65100 Van, Turkey

Received 23 July 2014; Revised 26 October 2014; Accepted 11 November 2014

Academic Editor: Bruce V. Taylor

Copyright © 2015 Mahmut Alpayci et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Loma and R. Heyman, “Multiple sclerosis: pathogenesis and treatment,” Current Neuropharmacology, vol. 9, no. 3, pp. 409–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. L. Weiner, “A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis,” Journal of Neurology, vol. 255, no. 1, pp. 3–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Hoffjan and D. A. Akkad, “The genetics of multiple sclerosis: an update 2010,” Molecular and Cellular Probes, vol. 24, no. 5, pp. 237–243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Pierrot-Deseilligny and J. C. Souberbielle, “Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?” Brain, vol. 133, no. 7, pp. 1869–1888, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. K. K. Oguz, A. Kurne, A. O. Aksu et al., “Assessment of citrullinated myelin by 1H-MR spectroscopy in early-onset multiple sclerosis,” American Journal of Neuroradiology, vol. 30, no. 4, pp. 716–721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Bradford, I. Ramos, A. K. Cross et al., “Localisation of citrullinated proteins in normal appearing white matter and lesions in the central nervous system in multiple sclerosis,” Journal of Neuroimmunology, vol. 273, no. 1-2, pp. 85–95, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Moscarello, F. G. Mastronardi, and D. D. Wood, “The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis,” Neurochemical Research, vol. 32, no. 2, pp. 251–256, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Ö. Ortancil, N. Bulmuş, Ş. Özdolap, S. Kiran, and M. Arasli, “Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and their relationship with extra-articular manifestations,” Turkish Journal of Rheumatology, vol. 26, no. 3, pp. 193–198, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Huang, Z. Xu, F. Wu et al., “The clinical value of serum anti-cyclic citrullinated peptide antibodies for juvenile idiopathic arthritis,” Turkish Journal of Rheumatology, vol. 27, no. 4, pp. 221–226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. C. H. Polman, S. C. Reingold, G. Edan et al., “Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”,” Annals of Neurology, vol. 58, no. 6, pp. 840–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  12. L. B. Pritzker, S. Joshi, J. J. Gowan, G. Harauz, and M. A. Moscarello, “Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D,” Biochemistry, vol. 39, no. 18, pp. 5374–5381, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. H. Almohmeed, A. Avenell, L. Aucott, and M. A. Vickers, “Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis,” PLoS ONE, vol. 8, no. 4, Article ID e61110, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Pratesi, C. Tommasi, C. Anzilotti, D. Chimenti, and P. Migliorini, “Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 54, no. 3, pp. 733–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Makrygiannakis, E. Af Klint, I. E. Lundberg et al., “Citrullination is an inflammation-dependent process,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1219–1222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Oreja-Guevara, J. Ramos-Cejudo, L. S. Aroeira, B. Chamorro, and E. Diez-Tejedor, “TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab,” BMC Neurology, vol. 12, article 95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Schulze-Koops and J. R. Kalden, “The balance of Th1/Th2 cytokines in rheumatoid arthritis,” Best Practice and Research: Clinical Rheumatology, vol. 15, no. 5, pp. 677–691, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Yamada, A. Suzuki, X. Chang, and K. Yamamoto, “Citrullinated proteins in rheumatoid arthritis,” Frontiers in Bioscience, vol. 10, no. 1, pp. 54–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Cui, K. E. Taylor, Y. C. Lee, H. Källberg, M. E. Weinblatt, and J. S. Coblyn, “The influence of polygenic risk scores on heritability of anti-CCP level in RA,” Genes & Immunity, vol. 15, no. 2, pp. 107–114, 2014. View at Google Scholar
  20. S. Sawcer, G. Hellenthal, and M. Pirinen, “Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis,” Nature, vol. 476, pp. 214–219, 2011. View at Publisher · View at Google Scholar
  21. J.-O. Kim, J.-S. Lee, J.-Y. Choi et al., “The relationship between peripheral arthritis and anti-cyclic citrullinated peptide antibodies in ankylosing spondylitis,” Joint Bone Spine, vol. 80, no. 4, pp. 399–401, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Uyanik, F. Albayrak, M. H. Uyanik, H. Dursun, M. Keles, and R. Cetinkaya, “Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever,” Rheumatology International, vol. 30, no. 4, pp. 467–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Zhao, J. Li, X.-X. Li, C. Li, L. Li, and Z.-G. Li, “What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus?” Joint Bone Spine, vol. 76, no. 5, pp. 501–507, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Gokhan, I. H. Turkeyler, T. Babacan et al., “The antibodies cyclic citrullinated peptides (anti-CCP) positivity could be a promising marker in brucellosis patients presented with peripheric arthritis,” Modern Rheumatology, vol. 24, no. 1, pp. 182–187, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Alpayci, N. Bozan, S. Erdem, M. Gunes, and M. Erden, “The possible underlying pathophysiological mechanisms for development of multiple sclerosis in familial Mediterranean fever,” Medical Hypotheses, vol. 78, no. 6, pp. 717–720, 2012. View at Publisher · View at Google Scholar · View at Scopus